Immunogenicity and Sustainability of the Immune Response in Brazilian HIV-1-Infected Individuals Vaccinated With Inactivated Triple Influenza Vaccine

被引:2
|
作者
Souza, Thiago Moreno L. [1 ,2 ,3 ]
Santini-Oliveira, Marilia [4 ]
Martorelli, Andressa [1 ,2 ,3 ]
Luz, Paula M. [4 ]
Vasconcellos, Mauricio T. L. [4 ]
Giacoia-Gripp, Carmem B. W. [5 ]
Morgado, Mariza [5 ]
Nunes, Estevao P. [4 ]
Lemos, Alberto S. [4 ]
Ferreira, Ana C. G. [4 ]
Moreira, Ronaldo I. [4 ]
Veloso, Valdilea G. [4 ]
Siqueira, Marilda [1 ]
Grinsztejn, Beatriz [4 ]
Camacho, Luiz A. B. [6 ]
机构
[1] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, NIC WHO, Lab Virus Resp & Sarampo, Rio De Janeiro, Brazil
[2] Fundacao Oswaldo Cruz, Ctr Desenvolvimento Tecnol Saude, Rio De Janeiro, Brazil
[3] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil
[4] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil
[5] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil
[6] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil
关键词
influenza; vaccine; HIV; immunogenicity; vaccine mismatch; SEASONAL INFLUENZA;
D O I
10.1002/jmv.24351
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-infected individuals have a higher risk of serious illnesses following infection by infection with influenza. Although anti-influenza vaccination is recommended, immunosuppression may limit their response to active immunization. We followed-up a cohort of HIV-infected individuals vaccinated against influenza to assess the immunogenicity and sustainability of the immune response to vaccination. Individuals were vaccinated 2011 with inactivated triple influenza vaccine (TIV), and they had received in 2010 the monovalent anti-A(H1N1)pdm09 vaccine. The sustainability of the immune response to A (H1N1) pdm09 at 12 months after monovalent vaccination fell, both in individuals given two single or two double doses. For these individuals, A(H1N1) pdm09 component from TIV acted as a booster, raising around 40% the number of seroprotected individuals. Almost 70% of the HIV-infected individuals were already seroprotected to A/H3N2 at baseline. Again, TIV boosted over 90% the seroprotection to A/H3N2. Anti-A/H3N2 titers dropped by 20% at 6 months after vaccination. Pre-vaccination seroprotection rate to influenza B (victoria lineage) was the lowest among those tested, seroconversion rates were higher after vaccination. Seroconversion/protection after TIV vaccination did not differ significantly across categories of clinical and demographic variables. Anti-influenza responses in Brazilian HIV-infected individuals reflected both the previous history of virus circulation in Brazil and vaccination. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:426 / 436
页数:11
相关论文
共 50 条
  • [31] Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1-Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa
    Kaleebu, Pontiano
    Njai, Harr Freeya
    Wang, Lei
    Jones, Norman
    Ssewanyana, Isaac
    Richardson, Paul
    Kintu, Kenneth
    Emel, Lynda
    Musoke, Philippa
    Fowler, Mary Glenn
    Ou, San-San
    Jackson, J. Brooks
    Guay, Laura
    Andrew, Philip
    Baglyos, Lynn
    Cao, Huyen
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : 268 - 277
  • [32] Immune response to influenza A(H1N1)v in HIV-infected patients
    Sansonetti, Paola
    Sali, Michela
    Fabbiani, Massimiliano
    Morandi, Matteo
    Martucci, Rosa
    Danesh, Ali
    Delogu, Giovanni
    Bermejo-Martin, Jesus F.
    Sanguinetti, Maurizio
    Kelvin, David
    Cauda, Roberto
    Fadda, Giovanni
    Rubino, Salvatore
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2014, 8 (01): : 101 - 109
  • [33] Long-term seroprotective response of trivalent seasonal influenza vaccine in HIV-infected children, regardless of immunogenicity before immunisation
    Moolasart, Visal
    Manosuthi, Weerawat
    Ausavapipit, Jarurnsook
    Chottanapund, Suthat
    Likanonsakul, Sirirat
    Uttayamakul, Sumonmal
    Srisopha, Somkid
    Lerdsamran, Hatairat
    Puthavathana, Pilaipan
    INTERNATIONAL JOURNAL OF STD & AIDS, 2016, 27 (09) : 761 - 768
  • [34] Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals
    Kaufmann, GR
    Duncombe, C
    Cunningham, P
    Beveridge, A
    Carr, A
    Sayer, D
    French, M
    Cooper, DA
    AIDS, 1998, 12 (13) : 1625 - 1630
  • [35] Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere
    Maruszak, H.
    Jeganathan, S.
    Smith, D. E.
    Robertson, P.
    Barnes, T.
    Furner, V.
    HIV MEDICINE, 2012, 13 (06) : 352 - 357
  • [36] Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals
    Yang Xiaodong
    Wang Xiuwen
    Zhang Xin
    Ding Haifeng
    Wang Hu
    Huang Tao
    Zhang Guanghui
    Duan Junyi
    Xia Wei
    Su Bin
    Jin Cong
    Wu Hao
    Zhang Tong
    中华医学杂志英文版, 2023, 136 (24)
  • [37] Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals
    Yang, Xiaodong
    Wang, Xiuwen
    Zhang, Xin
    Ding, Haifeng
    Wang, Hu
    Huang, Tao
    Zhang, Guanghui
    Duan, Junyi
    Xia, Wei
    Su, Bin
    Jin, Cong
    Wu, Hao
    Zhang, Tong
    CHINESE MEDICAL JOURNAL, 2023, 136 (24) : 2948 - 2959
  • [38] HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children
    Leahy, Timothy R.
    Goode, Michelle
    Lynam, Paul
    Gavin, Patrick J.
    Butler, Karina M.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2014, 8 (03) : 360 - 366
  • [39] A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice
    Hovden, Arnt-Ove
    Brokstad, Karl A.
    Major, Diane
    Wood, John
    Haaheim, Lars R.
    Cox, Rebecca J.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2009, 3 (01) : 21 - 28
  • [40] Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine Two Open-label, Randomized Trials
    Vesikari, Timo
    Richardus, Jan Hendrik
    Berglund, Johan
    Korhonen, Tiina
    Flodmark, Carl-Erik
    Lindstrand, Ann
    Silfverdal, Sven Arne
    Bambure, Vinod
    Caplanusi, Adrian
    Dieussaert, Ilse
    Roy-Ghanta, Sumita
    Vaughn, David W.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (07) : 774 - 782